Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc., as indicated in the metadata) on September 16, 2015. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California. The filing primarily serves to disclose a presentation used by management in meetings and conferences.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation (Exhibit 99.1) rather than a financial statement or earnings release containing specific quantitative data.
Material Changes
No material changes to financial performance or operations are reported in the text of this filing. The document solely references the attachment of a presentation dated September 2015.
Guidance, Outlook, and Risks
- Regulation FD Disclosure: The company is disclosing a presentation under Item 7.01. The information contained in the presentation is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Outlook: The filing text does not contain specific guidance or management commentary regarding future performance; these details are contained within the attached Exhibit 99.1, which is not included in the provided text.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation dated September 2015) for actual business updates, as the 8-K text only references its existence.
- Confirm the registrant name is Imprimis Pharmaceuticals, Inc., noting a discrepancy with the "Harrow, Inc." name in the request metadata.
- Note that the presentation materials are not legally "filed" with the SEC and carry different liability standards than formal financial reports.